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CHAPTER   3
Prophylactic Dosing of Vitamin K
 to Prevent Bleeding
Mauri Witt, Nina Kvist, Marianne Hørby Jørgensen, Jan B.F. Hulscher, 
Henkjan J. Verkade, Also,
on behalf of the Netherlands Study group of Biliary Atresia Registry (NeSBAR)






Based on a high incidence of Vitamin K deficiency bleeding (VKDB) in breastfed 
infants with thus far unrecognised cholestasis, such as biliary atresia (BA), the 
Dutch regimen to prevent VKDB in breastfed infants was changed from a daily oral 
dosage of 25 μg to 150 μg vitamin K. Infants continued to receive 1 mg of vitamin 
K orally at birth. We compared the efficacy of the 150-μg regimen with the 25-μg 
regimen and with the Danish regimen of a single intramuscular (IM) dose of 1 mg 
vitamin K at birth. 
Methods
Data were retrieved from the national BA registries: 25 μg group (Netherlands, 
January 1991 to February 2011); 150 μg group (Netherlands, March 2011 to January 
2015); and IM 1 mg group (Denmark, July 2000 to November 2014). We compared 
the incidence of VKDB in the groups.
 
Results
VKDB occurred in 45 of 55 (82%) infants of the 25 μg group, in 9 of 11 (82%) of the 
150 μg group, but in only 1 of 25 (4%) of the IM 1 mg group (P < .001). Forty per cent 
of all infants of the 25 μg group had an intracranial haemorrhage as presenting 
symptom, compared with 27% of the infants of the 150 μg group (P = .43). 
Intracranial haemorrhage was not observed in the IM 1 mg group (0%; P < .001). 
Conclusions
A vitamin K prophylactic regimen of 1 mg of vitamin K orally at birth followed 
by a daily oral dosage of either 25 or 150 μg fails to prevent VKDB in breastfed 
infants with still unrecognised BA. The data support 1 mg vitamin K IM at birth as 
prophylaxis against VKDB. 




Vitamin K deficiency can cause severe bleeding in breastfed infants owing to 
insufficient amounts of vitamin K in breastmilk.1 This bleeding, known as vitamin K 
deficiency bleeding (VKDB), can be classified according to the time of presentation: 
early (<24 hours of age), classic (first week after birth), and late (between 1 week 
and 6 months of age).2 In¾50% of patients with late VKDB, the bleeding location 
involves an intracranial haemorrhage, which is associated with high mortality and 
morbidity.3–5 The absorption of vitamin K is strongly dependent on the intestinal 
availability of bile acids. Diminished or absent intestinal delivery of bile, which 
occurs during cholestasis, puts infants especially at risk for malabsorption of 
vitamin K and other fat-soluble vitamins.6,7 Infants who have been breastfed 
exclusively are at the highest risk for late VKDB, particularly if the cholestasis has 
not yet been diagnosed.
Many countries have introduced prophylactic regimens of vitamin K 
supplementation to prevent VKDB (Table 1).8 The optimal dose, route, and 
frequency of administration of vitamin K, however, are still unclear. Oral and 
intramuscular (IM) regimens of vitamin K administration at birth have been proven 
effective in the prevention of classic VKBD.9 A single dose of IM vitamin K at birth 
can also prevent late VKDB.10 Between 1990 and February 2011, all infants in the 
Netherlands received a single oral dose of 1 mg vitamin K at birth, followed by 
a recommended daily oral supplementation of 25 μg vitamin K between week 2 
and 13 in breastfed infants.11 This regimen significantly decreased the incidence of 
late VKDB.12 Previously, however, we and others reported several cases of VKDB 
based on surveillance studies and studies in high-risk populations, despite strong 
indications of adherence to the recommendations. In fact, in >80% of infants 
with biliary atresia (BA), severe late VKDB was the presenting symptom.13 This 
observation was in sharp contrast to a very low incidence of VKDB as presenting 
symptom in BA patients in Denmark, where other prophylactic vitamin K regimens 
are used.14–17 The risk of VKDB in Dutch breastfed BA patients was 8 to 10 times 
higher than that of Danish BA patients, on either a weekly oral dose of 1 mg vitamin 
K or a single IM dose of 1 mg vitamin K at birth. Since March 2011, the prophylactic 
regimen was changed in the Netherlands; the recommended daily oral dose of 25 
μg vitamin K was increased to 150 μg daily for all breastfed infants from week 2 to 
13 of life. The single oral dose of 1 mg vitamin K at birth was maintained.
In the current study, we evaluated the preventive effect of the adapted Dutch 
guideline with respect to the incidence and severity of VKDB as the presenting 
symptom in breastfed children with BA. We compared the incidence and severity 




Table 1: Vitamin K prophylaxis in different countries 8
Country Vitamin K prophylaxis Incidence of VKDB
per 100.000 infants
Netherlands (1990-2011) 1 mg p.o. at birth, 25 µg p.o.  daily 
from week 2-13
3.2 (95% CI 1.2-6.9)
Germany 3x 2 mg p.o. (day 1, 4-10, 28-42) 0.44 (95% CI 0.2-0.9)
France 2 mg p.o. weekly for 6 months No data available
Switzerland 3x 2 mg p.o. (day 1, day 4, week 4) 0.87 (95% CI 0.24-2.24)
Denmark 1994-June 2000 2 mg p.o. at birth, 1 mg p.o. weekly 
for 3 months
0.0 (95% CI 0-0.9)
>June 2000 1 mg i.m. at birth No data available
United Kingdom 1 mg i.m. at birth 




Australia 0.5- 1 mg i.m.




Canada 1 mg i.m. at birth 0.37
United States 1 mg i.m. at birth No data available
METHODS
Study population
The Netherlands Study group on Biliary Atresia Registry (NeSBAR) has been a 
joint effort of the Dutch Society for Paediatrics Section of Gastroenterology, 
Hepatology, and Nutrition and the Dutch Society for Paediatric Surgeons. Data 
of all patients with BA born from January 1991 to January 2015 and treated in 1 
of the 6 specialised academic centres in the Netherlands were obtained from the 
NeSBAR database. Data of all Danish patients with BA born from July 2000 to 
November 2014 were retrieved from the Department of Paediatric Surgery at the 
University Hospital of Copenhagen (Rigshospitalet). Patients with a gestational 
age <37 weeks or birth weight <2000 g were excluded. Infants who were born 
abroad or were hospitalised from birth were also excluded. Relevant clinical data 
were obtained from the medical records. The study was performed according to 
the guidelines of the medical ethics committee of the University Medical Center 
Groningen. For anonymised, retrospective analysis of filed patient data, ethics 
approval is not required in our countries.
Ƥ
VKDB was defined as bruising, bleeding, or intracranial haemorrhage in infants 
younger than 6 months, not due to other coagulopathies, in combination with 
normalisation of the coagulopathy (partial thromboplastin time or activated 
partial thromboplastin time) after administration of vitamin K.2,7,13




In this study, we evaluated the incidence of VKDB in breastfed children with BA 
who had received 1 of 3 prophylactic regimens: 
1. 25 μg group: 1 mg orally at birth, followed by a daily oral dose of 25 μg  
vitamin K (Netherlands, January 1991 to February 2011); 
2. 150 μg group: 1 mg orally at birth, followed by a daily oral dose of 150 μg 
vitamin K (Netherlands, March 2011 to January 2015); and 
3. IM 1 mg group: a single IM dose of 1 mg vitamin K at birth (Denmark, July 2000 
to November 2014).
Results of the 25 μg and IM 1 mg groups from before 2003 and 2005, respectively, 
upon which the vitamin K prophylaxis in the Netherlands was adapted, were 
partially published previously.13,18 In the current study, we used these data, 
enriched with updated results on the new regimens, to compare the efficacy of the 
adaptation with regard to protection against VKDB.
Statistical Analysis
To analyse the clinical and biochemical data, we used a χ2 test in case of 
dichotomous parameters, 1-way analysis of variance for parameters with a normal 
distribution, and Kruskal–Wallis test for parameters with a nonnormal distribution. 
The relative risks and 95% confidence intervals for VKDB were calculated, and 
the Fisher exact test was used for the comparison of incidences of VKDB and 
intracranial haemorrhage between groups. A P value <.05 was considered 
statistically significant. All analyses were performed with SPSS (version 22.0; IBM 
Corp, Armonk, NY).
RESULTS 
From January 1991 to January 2015, 238 patients with BA were registered in 
NeSBAR. Sixty-two patients were excluded for various reasons (Figure 1). Of the 
remaining infants, 110 (62%) received formula feeding or a combination of formula 
feeding and breastfeeding. Fifty-five exclusively breastfed patients were included 
in the 25 μg group and 11 in the 150 μg group (Figure 1). Between July 2000 and 
November 2014, 52 patients were registered in the Danish Biliary Atresia Registry. 
Fifteen infants were excluded for various reasons (Figure 1). Twenty-five (68%) of 
the remaining 37 were exclusively breastfed and included in the IM 1 mg group 
(Figure 1). The incidences of BA in the Netherlands and Denmark were 1:19 000 and 
1:17 000, respectively (Table 2). Table 3 summarises the clinical characteristics 
of the 3 groups. Patients in each group had conjugated hyperbilirubinaemia, as 
expected. Median age at diagnosis was 34, 31, and 42 days for 25 μg, 150 μg, and 
IM 1 mg, respectively (P = .47). There were no statistically significant differences 
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Table 2: Patients and populations
25 Ɋg group 150 Ɋg group IM 1 mg group
Prophylactic regimen 1 mg oral at birth
25 μg daily oral
1 mg oral at birth
150 μg daily oral
1 mg IM at birth
No. of live birthsa 3 902 956 672 531 897 156
Enlisted in BA registry 203 35 52
Incidence of BA 1: 19 226 1: 19 215 1: 17 253
a Number of live births were obtained from Central Bureau of Statistics 
(http://statline.cbs.nl) and UN data (http://data.un.org). 





1 mg IM group
n= 25
P value
Male, n (%)a 21 (38%) 4 (36%) 14 (56%) 0.30
Birth weight, mean 
+SD (grams)b
3431 + 418 3404 + 630 3383 + 618 0.92
Median age at 
diagnosis, daysb
34 (3-72) 31 (17-96) 42 (6-127) 0.31
Weight at diagnosis, 
mean +SD (grams)b
4045 + 562 4131 + 761 4353 + 1058 0.47
Median total bilirubin, 
mmol/Lb
171 (74-418) 148 (92-286) 174 (72-414) 0.54
Median direct 
bilirubin, mmol/Lb
135 (57-284) 122 (81-247) 131 (61-312) 0.44
Median ASAT, U/Lb 190 (28-635) 169 (100-536) 238 (49-1205) 0.43
Median ALAT, U/Lb 117 (15-458) 132 (78-272) 127 (24-392) 0.64
a P value was determined using Chi square test
b P value was determined using Kruskal Wallis test 
Ƥ
In the 25 μg group, VKDB occurred in 45 of 55 (82%) patients. Twenty-one (38% of 
total) were diagnosed with multiple bleedings. Twenty-two (40%) presented with 
intracranial haemorrhage, diagnosed with computed tomography or MRI scan. 
VKDB occurred in 9 of 11 (82%) of the 150 μg group. Six (55%) of these patients 
had multiple bleedings, and three (27%) presented with intracranial haemorrhage. 
In the Danish IM 1 mg group, VKDB occurred in only 1 of the 24 (4%) breastfed 


















150 Ɋg vs. 
1 mg IM
RR 95% CI RR 95% CI
VKDB, n (%) 45 (82%) 9 (82%) 1 (4%) <0.001 1.0 0.7-1.4 20.5 2.9-142.4
ICB, n (%) 22 (40%) 3 (27%) 0 (0%) <0.001 1.5 0.5-4.1 * *
Multiple 
bleedings, n (%)
21 (38%) 6 (55%) 0 (0%) <0.001 0.7 0.4-1.3 * *
P values were determined using Fisher exact (Fisher-Freeman-Halton) test
* Data could not be computed because no cases present in the 1 mg IM group
VKDB= Vitamin K deficiency bleeding
ICB= Intracranial bleeding











GI-bleeding, n (%) 13  (24%) 4  (36%) 1  (4%) 0.03
Umbilical bleeding, n (%) 6    (11%) 1  (9%) 0  (0%) 0.19
Skin bleeding, n (%) 25  (45%) 6  (55%) 0  (0%) <0.001
Prolonged bleeding vein puncture, n (%) 12  (22%) 1  (9%) 0  (0%) 0.02
Intracranial bleeding, n (%) 22  (40%) 3  (27%) 0  (0%) <0.001
P values were determined using Fisher exact test
DISCUSSION
We evaluated whether a vitamin K prophylactic regimen of 1 mg vitamin K orally at 
birth followed by 150 µg daily during weeks 2 to 13 sufficiently prevented VKDB in 
breastfed infants. Our data in a high-risk group, i.e., undiagnosed children with BA, 
show that this regimen does not successfully prevent VKDB in these children, in 
contrast to a regimen consisting of a single IM injection of 1 mg vitamin K at birth.
This study shows that increasing the daily dose of the oral vitamin K prophylactic 
regimen from 25 to 150 µg fails to prevent VKDB in breastfed infants with yet 
undiagnosed BA. VKDB occurred in 82% of the infants and included several cases 
of intracranial haemorrhage, which has been associated with serious morbidity 
and high mortality.5 The risk of VKDB in breastfed infants with BA on a daily oral 
dose of 150 µg of vitamin K was 20-fold higher than on a single IM dose at birth. 
Compared with the former regimen of 25 µg, there was no significant difference in 
the incidence of VKDB.
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We studied the incidence of VKDB as the presenting symptom in breastfed infants 
with BA under 3 different prophylactic regimens. Because we used the nationwide 
databases in the Netherlands and Denmark, in which all patients with biliary atresia 
are registered, we minimised the risk of selection bias. Only biliary atresia patients 
who were not presented to an academic hospital could have been missed. Another 
argument pleading against selection bias is the calculated incidence of BA in our 
3 cohorts. The incidences of BA in the Netherlands and in Denmark were 1:19 000 
and 1:17 000, respectively (Table 2), which are similar to the reported incidences 
in other studies.19–21 There were no statistically significant differences in clinical 
characteristics between the groups that might affect the risk of VKDB.
The Health Council of the Netherlands recommended an oral regimen with 
increased daily dosages instead of a single IM dose because, in the latter situation, 
a relatively large group would receive prophylaxis when it did not really need it, 
namely the infants who at birth (or shortly thereafter) started with formula feeding 
rather than breastfeeding. Another motivation was that oral prophylaxis was 
regarded to be as effective as intramuscular prophylaxis, as long as the dosage 
was adequate. Previous studies showed that a weekly oral prophylaxis of 1 mg 
vitamin K in the first 3 months of life was highly effective in preventing VKDB.13,22 
The hypothesis at that time was that a weekly prophylaxis of 1 mg was more 
effective than 25 µg daily prophylaxis, as the cumulative dose per week was 6-fold 
higher in the weekly prophylaxis (1.05 vs. 0.175 mg). Our present data clearly show 
that this hypothesis needs to be rejected. The cumulative administration of 1.05 
mg vitamin K (150 µg daily) did not decrease the incidence of VKDB in our study 
population. It is unclear why a single, weekly dose of 1 mg is apparently effective,13 
in contrast to a similar dose subdivided over daily fractions. One could speculate 
that the fractional absorption of 1 larger dosage is higher than that of multiple 
small dosages, but data on fractional vitamin K absorption in infants are lacking. 
Also, compliance with the daily administration could play a role. However, in the 
patients studied, we found that, for most patients, it was noted that the parents 
had complied with daily administrations, whereas nothing was noted in a minority 
of the patients. We therefore feel that poor adherence is not the major explanation 
for our present findings.
Similarly, it has remained unexplained why formula-fed infants are protected 
against VKDB, despite a relatively low intake of vitamin K compared with breastfed 
infants with vitamin K prophylaxis (25 to 50 μg daily, based on 150 mL formula 
per kg body weight, and 150 μg daily, respectively).13 Together, these observations 
underline the need to understand in more detail, the absorption of vitamin K from 
the infant intestine, to prevent VKDB based on rational arguments.
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Intramuscular administration of vitamin K at birth has been demonstrated as an 
effective prevention of VKDB.10,12,23 Our present data confirm this observation, 
even upon analysis of a group of infants with an inherently higher risk of VKDB. 
A great benefit of this type of prophylaxis is that the prophylaxis does not depend 
on daily or weekly adherence to the advised administration or the still rather 
uncharacterised intestinal absorption of vitamin K in infants. Disadvantages of 
IM prophylaxis are pain and possibly hematoma at the site of the injection and, 
although extremely rare, complications such as osteomyelitis and intramuscular 
bleeding.9,18 In this study, data about side effects of IM administration have not 
been collected systematically. Golding et al. had suggested an increased risk of 
developing leukaemia and other malignancies after IM vitamin K prophylaxis.24 
After these disturbing results, however, several studies on this topic could not 
reproduce the original epidemiologic association. Ross and Davies reviewed 
the epidemiologic studies and found no evidence for the originally suggested 
relationship between IM vitamin K prophylaxis and the development of childhood 
cancer.25
CONCLUSIONS
We conclude that a prophylactic regimen for breastfed infants consisting of 1 mg 
vitamin K orally at birth, followed by either 25 or 150 µg daily during weeks 2 to 
13, does not sufficiently prevent VKDB in breastfed infants with still undiagnosed 
BA. We assume that this insufficient prevention is also present in infants with 
yet undiagnosed other forms of neonatal cholestasis. Efficient prevention was 
obtained by a regimen consisting of a single IM injection of 1 mg vitamin K at birth, 
as performed successfully in Denmark.
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